tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Mocchegiani F et al. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. 2014 Ann. Transplant. pmid:25347718
Fox BD et al. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. 2017 Ann. Transplant. pmid:29133776
Bäckman L and Persson CA An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. 2014 Ann. Transplant. pmid:24637379
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Gijsen VM et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. 2012 Apr-Jun Ann. Transplant. pmid:22743729
Czubkowski P et al. Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. 2014 Ann. Transplant. pmid:25409773
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Aguiar D et al. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. 2017 Ann. Transplant. pmid:28461684
Roan JN et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. 2013 Ann. Transplant. pmid:23792500
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
El-Agroudy AE et al. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. 2008 Ann. Transplant. pmid:19034223
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Mizuno S et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. 2013 Ann. Transplant. pmid:23845965
Kuypers DR Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. 2008 Ann. Transplant. pmid:18806728
Basu A et al. Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. 2011 Jul-Sep Ann. Transplant. pmid:21959503
Fukazawa K et al. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. 2011 Jul-Sep Ann. Transplant. pmid:21959523
Zegarska J et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. 2015 Ann. Transplant. pmid:26313036
Figurski MJ et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. 2012 Jan-Mar Ann. Transplant. pmid:22466911
Acott P and Babel N BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? 2012 Jan-Mar Ann. Transplant. pmid:22466913
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Schmid S et al. Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. 2014 Ann. Transplant. pmid:25123847
Baran DA and Galin ID "One size fits all": immunosuppression in cardiac transplantation. 2003 Ann. Transplant. pmid:12848376
Remiszewski P et al. Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". 2003 Ann. Transplant. pmid:15114933
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
Zahn A et al. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. 2013 Ann. Transplant. pmid:24088725
Garaix F et al. Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. 2018 Ann. Transplant. pmid:30093607
WÅ‚odarczyk Z et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. 2002 Ann. Transplant. pmid:12465429
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Tang JT et al. A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. 2018 Ann. Transplant. pmid:29735966
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Abdel Halim M et al. Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. 2010 Jan-Mar Ann. Transplant. pmid:20305320
Wu P et al. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. 2011 Jan-Mar Ann. Transplant. pmid:21436775
Foroncewicz B et al. Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. 2014 Ann. Transplant. pmid:25163829
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Mahalati K and Kahan BD Pharmacological surrogates of allograft outcome. 2000 Ann. Transplant. pmid:11217202
Garlicki M et al. Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. 2006 Ann. Transplant. pmid:17025026
Ruangkanchanasetr P et al. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. 2016 Ann. Transplant. pmid:27980321
Malinowski M et al. The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. 2009 Apr-Jun Ann. Transplant. pmid:19487793
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Snell GI et al. Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. 2013 Ann. Transplant. pmid:23921892
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Schmid FX Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. 1993 Annu Rev Biophys Biomol Struct pmid:7688608
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Tzakis AG et al. Intestinal transplantation. 1994 Annu. Rev. Med. pmid:7515221
Hanauer SB and Dassopoulos T Evolving treatment strategies for inflammatory bowel disease. 2001 Annu. Rev. Med. pmid:11160781
Pratt WB The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. 1997 Annu. Rev. Pharmacol. Toxicol. pmid:9131255
Nikitin AV [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. 2014 Antibiot. Khimioter. pmid:25051716
Romano S et al. FK506 binding proteins as targets in anticancer therapy. 2010 Anticancer Agents Med Chem pmid:21182472
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
Pourtier-Manzanedo A et al. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. 1991 Anticancer Drugs pmid:1724925
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Pinsk V et al. Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. 2017 Anticancer Res. pmid:28551651
Kalas W et al. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. 2003 Mar-Apr Anticancer Res. pmid:12820430
Harada N et al. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. 2018 Anticancer Res. pmid:30194210
Ling G et al. Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. 2018 Anticancer Res. pmid:29848681
Morisaki T et al. A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. 2000 Sep- Oct Anticancer Res. pmid:11131636
Gornet JM et al. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. 2001 Nov-Dec Anticancer Res. pmid:11911319
Gauthier C et al. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. 2003 Antimicrob. Agents Chemother. pmid:12709320
Del Poeta M et al. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 2000 Antimicrob. Agents Chemother. pmid:10681348
Steinbach WJ et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 2007 Antimicrob. Agents Chemother. pmid:17502415
Gao L et al. Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis. 2017 Antimicrob. Agents Chemother. pmid:28923863
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 2004 Antimicrob. Agents Chemother. pmid:15105118
Onyewu C et al. Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 2007 Antimicrob. Agents Chemother. pmid:17664323
Lamoth F et al. In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. 2013 Antimicrob. Agents Chemother. pmid:23165466
Reedy JL et al. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 2006 Antimicrob. Agents Chemother. pmid:16569889
Katiyar SK et al. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. 2012 Antimicrob. Agents Chemother. pmid:23027185
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Sun S et al. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. 2008 Antimicrob. Agents Chemother. pmid:18056277
Kontoyiannis DP et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 2008 Antimicrob. Agents Chemother. pmid:18070977
Ricardo E et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. 2014 Antimicrob. Agents Chemother. pmid:24867987
Gao L and Sun Y In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. 2015 Antimicrob. Agents Chemother. pmid:26303797
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Roy J et al. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. 2002 Antimicrob. Agents Chemother. pmid:12384349
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 2004 Antimicrob. Agents Chemother. pmid:15561883
Sugita T et al. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. 2006 Antimicrob. Agents Chemother. pmid:16870799
Dang W et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. 2017 Antimicrob. Agents Chemother. pmid:28807916
Aoki Y and Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. 1999 Antimicrob. Agents Chemother. pmid:10543746
Dannaoui E et al. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. 2009 Antimicrob. Agents Chemother. pmid:19451295
Rivosecchi RM et al. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. 2017 Antimicrob. Agents Chemother. pmid:28674051
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Venkataramanan R et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. 2002 Antimicrob. Agents Chemother. pmid:12183280